Once-Yearly Reclast(R) Demonstrates Highly Significant Fracture Risk Reductions In The Treatment Of Postmenopausal Osteoporosis, New Study Shows Part 3

Zoledronic acrid 5mg, underneath the pile laugh at by manner of the cross of describe Aclasta(R), hold be conceded within in the region of 50 country general, in joint effort with the EU and Canada, in favour of the psychotherapy of Paget's virus. The U.S.

Food and Drug Administration (FDA) distribute an "approvable letter" for Reclast for the treatment of Paget's disease of the clean in February 2006. The FDA submission secondary background from the ongoing clinical undertaking program in osteoporosis. Novartis be in employment beside the FDA to gain agreement for this announcement. Zoledronic acid, the alive part of Reclast, is also untaken under the brand name Zometa(R) for apply in other indication.

About Postmenopausal Osteoporosis Postmenopausal osteoporosis (PMO) is a profound specification affecting millions of women worldwide. Osteoporosis at bequest affect an near 50.7 million empire in the UK, France, Germany, Italy, Spain, the USA and Japan.(3) Incidence of hip fracture in women is projected to twine by 240% worldwide by 2050, in place of populations burgeon and age.(9) Disclaimer The foregoing delivery encompass forward-looking statement that can be identified by the use of gobbledygook such as "may," "believe," "potentially," "potential," or corresponding expressions, or by in righteous shape out aware or implied planning concerning plausible regulatory filings, approvals or just round the corner public sale for Reclast. Such forward-looking statements require certain and unknown risk, uncertainties and other factor that may do actual grades with Reclast to be materially distinct from any future results, reading or conquest expressed or implied by such statements. There is no contract that Reclast will be approved by the U.S. Food and Drug Administration or any other regulatory authority for any indication in any open market. Neither can within be any guarantee regarding potential future sales of Reclast. In specific, management's means to ensure contentment of any condition authorities' requirements is not guaranteed and management's expectations regarding commercialization of Reclast could be exaggerated by, among other things, astonishing regulatory measures or snag or senate law roughly; unexpected clinical trial results, including exotic clinical data and additional analysis of in years clinical data; the company's ability to acquire or row rights or other proprietary learner wealth safety; jealousy in undivided; government, industry and general hoi polloi price restraint; and other risks and factors referred to in Novartis AG's common Form 20-F on transcription with the Securities and Exchange Commission of the United States. Should one or more of these risks or uncertainties materialize, or should underlying assumption prove erroneous, actual results may alter materially from those anticipated, believed, estimated or looked-for. Novartis is providing the news here clasp release commencing this date and do not occupy in any must to update any forward-looking statements contained in this press release as a upshot of new information, future measures or otherwise.

questions about cialis super active online

Press to learn here more buy generic cialis professional

More women's health blogs